The Sugar.IQ smart diabetes assistant is the latest example of how artificial intelligence is changing the way people manage chronic conditions like diabetes.
News & Features
Dexcom could face even more intense pressure in the CGM market now that Senseonics said its Eversense system has approval. The device could provide long-term continuous monitoring for up to three months.
The Irvine, CA-based company is making significant progress with its next generation TAVR device and could receive CE mark by the second half of 2019.
Swedish orthobiologics company BoneSupport said Zimmer Biomet has canceled most of its orders for the next three months. This follows BoneSupport's earlier decision to set up its own U.S. distribution network and terminate its agreement with Zimmer Biomet.
Bridge Connector is taking on healthcare's interoperability challenge with an integration platform as a service designed to help healthcare organizations streamline data.
MedAware finds a partner in Allscripts as it moves forward with commercialization efforts in the U.S.
Meet the six finalists in the Ascensia Diabetes Challenge, a global innovation competition designed to find digital solutions to transform Type 2 diabetes management.
Medtronic said its relationship with Nutrino's FoodPrint will leverage food data analytics across its diabetes portfolio.
Equashield’s robotic technology can help transport and handle dangerous drugs in hospital and healthcare facilities.
Neural Analytics has received CE mark and FDA clearance for a robotics-based ultrasound guidance system to observe blood flow to the brain.
Roche agreed to pay $2.4 billion to acquire the remaining shares of Foundation Medicine, a company that develops genomic profiling assays to pair cancer patients with relevant treatments and clinical trials.